Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen said it is charging $56,000 for an annual course of the new treatment, higher than the $10,000 to $25,000 price some Wall Street analysts were expecting.

Biogen's Alzheimer's drug could cost Medicare billions of dollars a year, report finds

American Airlines

Agios Pharmaceuticals

Dow Inc

Medtronic

Nielsen Hlds

NetApp

Zoom Video

With the trading day about halfway over, the markets were moving higher, after being stuck in the doldrums for the first half of the week.

American Airlines, Biogen, Dow and More Thursday Afternoon Analyst Calls

Biogen Inc (NASDAQ:BIIB) shares are trading higher by 3.2% at $419.81 after SVB Leerink maintained an Outperform on the stock and raised its price target from $380 to $475. The stock is also experiencing continued volatility following FDA accelerated approval of its Alzheimer's candidate.

Why Biogen Shares Are Trading Higher Today

Critics charge the FDA has been compromised and approved Biogen's Alzheimer's drug before it is proven to work. The post Biogen Gets an Unearned Rip on an Unproven Drug appeared first on InvestorPlace.

Biogen Gets an Unearned Rip on an Unproven Drug

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new research supporting the continued development of an investigational higher dose of SPINRAZA® (nusinersen) and additional data reinforcing the strength of SPINRAZA's clinical profile in improving the lives of individuals with spinal muscular atrophy (SMA) over the long term. These data are being presented at the virtual Cure SMA Research & Clinical Care Meeting taking place June 9-11, 2021.

New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen's Commitment to Innovation in SMA Therapy

We believe that the stock price of ​Biogen, a biotechnology company focused on treatments for neurological diseases, looks attractive at current levels of $396, despite it being up 38% from the levels of around $290 it was at yesterday morning. The sharp jump in BIIB stock can be attributed to the.

Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday

Biogen Inc (NASDAQ:BIIB) has priced its newly approved Alzheimer's drug aducanumab much higher than expected, broker Credit Suisse said in a note today, with analysts suggesting a resurgence of new product development into the disease will follow as a result Shares in the US firm rocketed when the US Food and Drug Administration approved the treatment on Monday capping a remarkable resurgence in fortunes both for the drug and Biogen. Biogen had stopped a phase III trial in March 2019 on a recommendation it would not meet its final endpoint, only to start it again in October after reviewing the data further.

Biogen's hefty price tag for new drug forecast to spark Alzheimer's research resurgence

The shares of Biogen, Inc (NASDAQ: BIIB) have received a price target increase from $216 to $382 from Baird. These are the details.

BIIB Stock Price: $382 Target From Baird

The Aduhelm effect seems to be quickly wearing off the stock.

Biogen Sinks Despite Raft of Analyst Upgrades

Sen. Ron Wyden calls Aduhelm's $56,000 price tag "unconscionable."

Senator Takes Aim at Biogen's New Alzheimer's Drug

Shares Biogen Inc. pulled back 1.4% in afternoon trading Tuesday, in the wake of the company's conference call with analysts following the approval of Aduhelm by the Food and Drug Administration to treat Alzheimer's disease. The decline comes a day after the stock skyrocketed 38.3% on the approval.

Biogen expects its $56,000 Alzheimer's drug to be covered by Medicare for 'most' patients

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 2 0 0 0 Somewhat Bullish 1 1 1 0 Indifferent 4 0 1 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 11 analysts have offered 12-month price targets for Biogen. The company has an average price target of $382.27 with a high of $500.00 and a low of $245.00.

Where Biogen Stands With Analysts

Biogen Inc. (NASDAQ:BIIB) shares pulled back on Tuesday to trim Monday's gains. The biotechnology stock rallied more than 38% after the FDA approved its Alzheimer's drug, aducanumab.

Biogen skyrockets after Alzheimer's drug approval – time to buy?

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%.  The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from $343 to $455.

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

June 7th the FDA approved aducanumab for Alzheimer's disease. This was despite the advisory committee voting overwhelmingly against approval.

Biogen's Aducanumab Approval: Making The Advisory Committee Irrelevant

The Food and Drug Administration (FDA) approved Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's disease drug aducanumab on Monday. This makes the drug, to be marketed as Aduhelm, the first and only treatment to be granted approval to slow cognitive decline in people living with Alzheimer's disease.

Dr. Karlawish on Biogen's Alzheimer's drug approval: ‘another study is needed'

The company said is it charging $56,000 for an annual course of the treatment, higher than the $10,000 to $25,000 price some analysts were expecting.

Biogen faces tough questions over $56K a year price of newly approved Alzheimer's drug

FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab

Warren Buffett's Berkshire Hathaway scored a $60 million gain on Biogen shares after they surged to a record high on Monday. Federal regulators approved the biotech company's Aduhelm drug — the first Alzheimer's treatment to get the green light in nearly 20 years, and the first to target the underlying process of the cognitive disease. The famed investor's conglomerate bought nearly 650,000 shares of the drugmaker in the fourth quarter of 2019, giving it a stake worth $192 million at the year's end. It trimmed the position to 643,000 shares during the next quarter, but hasn't touched it since.

Warren Buffett's Berkshire Hathaway scores $60 million gain on Biogen after FDA approval sends the stock to record high

There are still some risks for the biotech stock. But they're a lot lower now, with its Alzheimer's disease drug likely to make billions of dollars.

Should You Buy Biogen Stock After Its Stunning FDA Win?

"Desperation should drive funding for Alzheimer's research, it should not drive the interpretation of scientific evidence," Karlawish said.

Dementia expert says evidence behind Biogen Alzheimer's drug 'wasn't sufficient' for FDA approval

Athira Pharma

The approval on Monday of the first new drug for Alzheimer's disease in nearly two decades — Biogen's aducanumab — helps shine a light on a path forward for other companies developing Alzheimer's therapies, including Seattle-based Athira Pharma, which saw its stock rise more than 4% off the Biogen news.

Approval of Biogen's drug for Alzheimer's disease may ease path for others such as Athira Pharma

Biogen closed the day up 38% but had been up as much as 60% on the news, and this came after a brief halt in share trading.

Biogen's Alzheimer Drug Wins FDA Approval

The approval by U.S. regulators on Monday of a Biogen Inc drug to treat Alzheimer's disease could reinvigorate investor interest more broadly in biotech and pharmaceutical shares that have struggled in 2021.

News for Biogen Stock (BIIB)